Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study To Assess The Safety And Tolerability Of BEMA Buprenorphine NX In Opioid Dependent Subjects (BNX-201)

Next Previous
Trial Profile

An Open Label Study To Assess The Safety And Tolerability Of BEMA Buprenorphine NX In Opioid Dependent Subjects (BNX-201)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 16 Mar 2015 A sNDA submission is anticipated by the fourth quarter of 2015, according to a BioDelivery Sciences International media release.
  • 07 Aug 2013 Based on outcomes of this trial, and a bioequivalence trial, an NDA was submitted to the FDA for BUNAVAIL [buprenorphine/naloxone], according to a BioDelivery Sciences International media release issued on 1 August 2013.
  • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top